Iambic Therapeutics, backed by Nvidia and QIA, files for US IPO
The drug developer, which has raised $461.8 million, joins a series of biotech listings capitalising on drug advancements and M&A activity this year.
Biotech IPO surge continues
Iambic Therapeutics, a drug developer backed by chip giant Nvidia and Qatar Investment Authority (QIA), initiated its US initial public offering (IPO) process on Monday, 21 September. The company plans to list on the Nasdaq exchange under the symbol "IAM".
This move adds to a busy period for biotechnology listings in the autumn, with J.P. Morgan, Jefferies, BofA Securities, and Citigroup serving as underwriters for the offering. Despite broader market uncertainties, including rising bond yields and interest rate hikes, the biotech sector's IPO activity has remained resilient.
AI-driven drug discovery
Founded in 2019 as Entos, Iambic focuses on developing drug candidates using its artificial intelligence (AI) platform. The company's pipeline includes IAM1363, an early-stage candidate for treating solid tumours such as breast cancer. Earlier on Monday, Iambic and drugmaker AbbVie unveiled a multi-year collaboration to accelerate AI-driven discovery of small molecule therapies.
Iambic also maintains partnerships with other pharmaceutical firms, including Takeda, Lundbeck, Revolution Medicines, Jazz Pharmaceuticals, and Bayer.
Strong investor interest
Iambic has secured approximately $461.8 million in funding since its inception from technology and healthcare investors. Beyond Nvidia and QIA, its significant backers include investment firms Catalio, Nexus Ventures, and Coatue Management.
The biotech sector's sustained issuance this year is driven by strong drug advancements and a wave of acquisitions by larger pharmaceutical companies. Matt Kennedy, a senior strategist at Renaissance Capital, noted that all five of this year's top-performing IPOs (with deal sizes over $50 million) are from the biotechnology industry.
This robust activity in US biotech IPOs shows a continued appetite for innovation-driven healthcare investments, even amidst global economic shifts. For Asian investors, particularly sovereign wealth funds like QIA, this indicates a strategic focus on next-generation pharmaceutical development and AI integration.
Companies in Asia pursuing similar AI-driven drug discovery models may observe these listings as benchmarks for valuation and investor interest, potentially influencing future funding rounds and partnership strategies within the region's burgeoning biotech ecosystem.
This article is journalism, not investment advice; consult a licensed professional before making financial decisions. Market data is indicative, may be delayed, and should be verified with your broker or exchange before use.
Comments.
Comments are moderated. We remove what is unlawful, abusive or off-topic, and and you remain responsible for what you post.
Reader comments open soon. Until then, corrections and responses go to our newsroom, and we publish what we get wrong on Corrections.